1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-15.84%
Cash & equivalents declining -15.84% while Drug Manufacturers - Specialty & Generic shows -7.24% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-15.84%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -5.48%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
5.73%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
17.28%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 1.92%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
No Data
No Data available this quarter, please select a different quarter.
-1.76%
Near the Drug Manufacturers - Specialty & Generic median of -1.91%. Charlie Munger sees typical short-term asset management among peers.
0.51%
PP&E growth below half of Drug Manufacturers - Specialty & Generic median of -1.19%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
0.74%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
5.44%
Intangibles growth < half the Drug Manufacturers - Specialty & Generic median of -1.82%. Joel Greenblatt sees fewer intangible expansions vs. peers. Possibly less impairment risk.
2.34%
Below half of Drug Manufacturers - Specialty & Generic median of -1.62%. Joel Greenblatt sees relatively minimal intangible expansions vs. peers.
-20.11%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
91.46%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
1.35%
Below half the Drug Manufacturers - Specialty & Generic median of -0.90%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
0.97%
Below half the Drug Manufacturers - Specialty & Generic median of -1.21%. Jim Chanos might see potential stagnation or distress vs. peers.
8.11%
Payables growth below half of Drug Manufacturers - Specialty & Generic median of -0.73%. Joel Greenblatt sees more conservative payables management vs. peers.
117.84%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-63.03%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-35.30%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-50.43%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-10.32%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects potential working capital strain.
-11.94%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
8.16%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
-8.75%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-10.21%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.31%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-10.23%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.46%. Jim Chanos suspects an alarming rise in overall leverage.
4.35%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
8.18%
Below half Drug Manufacturers - Specialty & Generic median of -1.58%. Jim Chanos suspects poor profitability or large dividend drains.
-89.47%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
4.30%
Below half Drug Manufacturers - Specialty & Generic median of -0.53%. Jim Chanos suspects slower net worth growth or losses vs. peers.
0.97%
Below half Drug Manufacturers - Specialty & Generic median of -1.21%. Jim Chanos suspects a major slowdown or distress.
-20.11%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-8.37%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.87%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-3.06%
Below half of Drug Manufacturers - Specialty & Generic median 4.22%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
